The global incretin-based drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The incretins are gastrointestinal polypeptide hormones. They act to modulate insulin secretion from pancreatic beta cells. The major factor driving the growth of the market is the increasing prevalence of diabetes across the globe.
According to the International Diabetes Federation (IDF), in 2021, approximately 537 million adults aged 20-79 years has diabetes globally with 3 in 4 adults with diabetes living in low- and middle-income countries with a mortality rate of 6.7 million people globally. Additionally, the total number of people living with diabetes is anticipated to rise to 643 million by 2030 and 783 million by 2045. Moreover, almost 1 in 2 (240 million) adults living with diabetes are undiagnosed. Hence, the increasing prevalence of diabetes is driving the demand for incretin-based drugs for the treatment which in turn is driving the growth of the market.
To Request a Sample of our Report on Incretin-Based Drugs Market: https://www.omrglobal.com/request-sample/incretin-based-drugs-market
Some major players in the market include Novo Nordisk A/S, Eli Lilly and Company, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2022, Novo Nordisk announced the launch of oral semaglutide in India. Oral semaglutide is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Drug Type
- By Route of Administration
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Novo Nordisk A/S, Eli Lilly and Company, and Novartis International AG, among others.
(Get 15% Discount on Buying this Report)
A full Report of Incretin-Based Drugs Market is Available @ https://www.omrglobal.com/industry-reports/incretin-based-drugs-market
Global Incretin-Based Drugs Market Report by Segment
By Drug Type
- Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
- Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
By Route of Administration
- Oral
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Incretin-Based Drugs Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
